Literature DB >> 26342868

Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.

Zhouling Xie1, Youli Zhou1, Wei Zhao2, He Jiao1, Yu Chen1, Yong Yang2, Zhiyu Li3.   

Abstract

A series of AG014699 derivatives containing a novel scaffold of 2,3-dihydro-1H-[1,2]diazepino[4,5,6-cd]indole-1,4(6H)-dione were synthesized and evaluated for their inhibitory activities toward PARP-1 enzyme and two cell lines, MCF-7 cells and the BRCA1-deficient MDA-MB-436 cells. Our results demonstrated that of all AG014699 derivatives synthesized in this work, compounds 6 and 7 showed strong PARP-1 inhibitory activity (IC50=3.5 nM and 2.4 nM, respectively), only four and three times less potent than AG014699. Compound 6 also had significantly cell inhibitory activity against both MCF-7 cells (CC50=25.8 μM) and the BRCA1-deficient MDA-MB-436 cells (CC50=5.4 μM), nearly as good as AG014699, indicating that it can be a promising compound for further evaluation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRCA1/2-deficient; DNA damage; Inhibitor; Molecular docking; Poly ADP-ribose polymerase-1 (PARP-1)

Mesh:

Substances:

Year:  2015        PMID: 26342868     DOI: 10.1016/j.bmcl.2015.08.060

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

Review 1.  PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.

Authors:  Clifford M Csizmar; Antoine N Saliba; Elizabeth M Swisher; Scott H Kaufmann
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.